WT1 and myelodysplastic syndrome: Using a standardized ELN-certified assay we here showed that the transcription factor WT1 was overexpressed on mRNA level in 57% of patients with MDS and that PB WT1-mRNA overexpression strongly correlated with disease categories and risk stages according to WHO 2016 classification and IPSS-R respectively.